Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs. The company’s core strengths include the acquisition and management of highly regulated raw materials, and specialized chemistry, formulation and manufacturing capabilities. The company’s Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Nuclear Imaging segment includes nuclear imaging agents. Mallinckrodt Pharmaceuticals provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity, national origin, age, disability, veteran status, or genetics. In addition to federal law requirements, Mallinckrodt Pharmaceuticals complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation and training.
Surrey, GB
Size (employees)
4,500 (est)
Mallinckrodt Pharmaceuticals was founded in 1867 and is headquartered in Surrey, GB
Report incorrect company information

Mallinckrodt Pharmaceuticals Office Locations

Mallinckrodt Pharmaceuticals has an office in Hazelwood, Surrey and Dublin
Surrey, GB (HQ)
Lotus Park The Causeway
Dublin, IE
Hazelwood, US
675 James S McDonnell Blvd
Show all (3)
Report incorrect company information

Mallinckrodt Pharmaceuticals Financials and Metrics

Mallinckrodt Pharmaceuticals Financials

Mallinckrodt Pharmaceuticals's revenue was reported to be £64.98 m in FY, 2016

Revenue (FY, 2016)

65 m

Gross profit (FY, 2016)

8.5 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

1.5 m

EBITDA (FY, 2016)

1.9 m

EBIT (FY, 2016)

1.8 m

Market capitalization (2-Oct-2017)

3.1 b

Closing share price (2-Oct-2017)

Mallinckrodt Pharmaceuticals's current market capitalization is $3.1 b.
GBPFY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016


38 m36.6 m45.4 m71.6 m65.9 m72.6 m79.6 m89.7 m62.6 m64.2 m65 m

Revenue growth, %


Cost of goods sold

31.6 m31.5 m36.3 m56 m56.4 m65 m70.6 m79.8 m56.3 m55.4 m56.5 m

Gross profit

6.5 m5.1 m9 m15.6 m9.5 m7.6 m9 m9.9 m6.3 m8.8 m8.5 m
GBPFY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

2 m1.2 m2.7 m5.9 m3.9 m(7.9 m)3.3 m3 m1.9 m1.9 m1.5 m

Income Taxes Paid

(748 k)(528 k)(117 k)
GBPY, 2016


11.4 k

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information